Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced that the first patient has been enrolled in the VITAL-CML trial, w ...
- OPTIC trial evaluating response-based dosing regimens of ponatinib in patients with resistant CP-CML met primary endpoint, confirming optimal benefit-risk profile achieved via 45mg/day starting dose ...
The OPTIC trial, which evaluated treatment in patients with resistant disease, with and without mutations, met its primary endpoint. The study demonstrates that the optimal benefit-risk profile for ...
Start of clinical program in chronic myeloid leukemia As part of its updated clinical strategy communicated end of 2025, Mendus is expanding clinical development of the lead product vididencel to incl ...
BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, ...
FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows ...
A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute ...
Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results